Asia Pacific Pharma Sector Analysis

  • June 2012
  • -
  • RNCOS
  • -
  • 160 pages

The Asia-Pacific region is emerging as the fastest growing pharmaceutical industry in the global pharmaceutical arena. In the recent years, the demand for healthcare services has risen among the region’s populations. According to our new research report, the low operating costs and skilled manpower continue to attract pharmaceutical companies towards Asia Pacific, which is now emerging as a powerhouse of pharmaceutical Research & Development (R&D). The future of the industry in the region remains bright, and is projected to grow at a compound annual rate of around 10% during 2012-2015.

The report, “Asia Pacific Pharma Sector Analysis”, finds that the market growth will mainly be driven by factors, like changing regulatory environment, increasing disposable incomes, rising prevalence of lifestyle diseases, and significant developments in the field of contract manufacturing, particularly in APIs. On studying the pharmaceutical market in each country, we observed that mature markets such as Japan and Australia are experiencing slower growth rates, while emerging as new market leaders, China and India are enjoying investments by foreign pharmaceutical companies. South Korea and New Zealand are relatively small markets, with the growth limited by the size of these island nations. We have also studied the market scenario in Indonesia, Thailand, the Philippines, Malaysia and Vietnam.

We also found out why the Asia-Pacific region is emerging as a new destination for the generic drugs industry. As per our findings, the western countries face the issue of poorly defined regulatory pathways, and a few Asian countries are well positioned to benefit from these changes, attracting huge investments by generic companies. The OTC sector in the region has also been expanding rapidly. The study of other emerging trends revealed that the growing market for vaccines and medical tourism is giving new dimension to the region’s pharmaceutical industry. Though Asia-Pacific is emerging as a right place for the drug-related research, the region lacks IPR regime. The report provides in-depth information about regulatory environment and key market players in each country. This way, our research work aims at presenting a fair picture of the industry to clients.

Table Of Contents

1. Analyst View
2. Research Methodology
3. Global Pharmaceutical Market Overview
3.1 Leading Drugs in Global Pharma Market
4. Asia-Pacific Pharmaceutical Market Scenario
5. Country-level Analysis: Studying the Future Market
5.1 China
5.1.1 Market Overview
5.1.2 Regulatory Environment
5.1.3 Key Players
5.2 India
5.2.1 Market Overview
5.2.2 Regulatory Environment
5.2.3 Key Players
5.3 Japan
5.3.1 Market Overview
5.3.2 Regulatory Environment
5.3.3 Key Players
5.4 South Korea
5.4.1 Market Overview
5.4.2 Regulatory Environment
5.4.3 Key Players
5.5 Indonesia
5.5.1 Market Overview
5.5.2 Regulatory Environment
5.5.3 Key Players
5.6 Vietnam
5.6.1 Market Overview
5.6.2 Regulatory Environment
5.6.3 Key Players
5.7 Thailand
5.7.1 Market Overview
5.7.2 Regulatory Environment
5.7.3 Key Players
5.8 Philippines
5.8.1 Market Overview
5.8.2 Regulatory Environment
5.8.3 Key Players
5.9 Malaysia
5.9.1 Market Overview
5.9.2 Regulatory Environment
5.9.3 Key Players
5.10 Australia
5.10.1 Market Overview
5.10.2 Regulatory Environment
5.10.3 Key Players
5.11 New Zealand
5.11.1 Market Overview
5.11.2 Regulatory Environment
5.11.3 Key Players
6. Emerging Market Trends
6.1 Growing CRO Market
6.2 Rising Development of New Vaccines
6.3 Increasing Demand of Generic Drugs
6.4 Booming Medical Tourism Market

List of Figures:

Figure 3-1: Global - Pharmaceutical Market (Billion US$), 2010-2015
Figure 3-2: Global - Breakup of Pharmaceutical Market by Region (%), 2010
Figure 4-1: Asia-Pacific - Pharmaceutical Market (Billion US$), 2010-2015
Figure 4-2: Asia-Pacific - Pharmaceutical Market by Country (%), 2011
Figure 4-3: Asia-Pacific - Forecast for Pharmaceutical Market by Country (%), 2015
Figure 5-1: China - Pharmaceutical Market (Billion US$), 2010-2015
Figure 5-2: China - Share of Imported and Domestically Manufactured Drugs in Pharma Market (2010)
Figure 5-3: China - Share of Generic Drugs in Pharma Market (2011)
Figure 5-4: China - Share of OTC and Prescription Drugs in Pharma Market (2011)
Figure 5-5: China - Pharmaceutical Exports and Imports (Billion US$), 2009 and 2010
Figure 5-6: India - Pharmaceutical Market (Billion US$), FY 2010-FY 2015
Figure 5-7: India - Share of Imported and Domestically Manufactured Drugs in Pharma Market (FY 2011)
Figure 5-8: India - Share of Generics and Branded Drugs in Pharma Market (2011)
Figure 5-9: India - Share of OTC and Prescription Drugs in Pharma Market (2011)
Figure 5-10: India - Pharmaceutical Exports and Imports (Billion US$), FY 2009 and FY 2010
Figure 5-11: Japan - Pharmaceutical Market (Billion US$), 2010-2015
Figure 5-12: Japan - Share of Imported and Domestically Manufactured Drugs in Pharma Market (2010)
Figure 5-13: Japan - Share of Generics and Branded Drugs in Pharma Market (2011)
Figure 5-14: Japan - Share of OTC and Prescription Drugs in Pharma Market (2011)
Figure 5-15: Japan - Pharmaceutical Exports and Imports (Billion US$), 2009 and 2010
Figure 5-16: South Korea - Pharmaceutical Market (Billion US$), 2010-2015
Figure 5-17: South Korea - Share of OTC and Prescription Drugs in Pharma Market (2011)
Figure 5-18: South Korea - Share of Generics and Branded Drugs in Pharma Market (2011)
Figure 5-19: South Korea - Pharmaceutical Export (Billion US$), 2008-2010
Figure 5-20: Indonesia - Pharmaceutical Market (Billion US$), 2010-2015
Figure 5-21: Indonesia - Share of OTC and Prescription Drugs in Pharma Market (2011)
Figure 5-22: Indonesia - Share of Generics and Branded Drugs in Pharma Market (2011)
Figure 5-23: Vietnam - Pharmaceutical Market (Billion US$), 2010-2015
Figure 5-24: Vietnam - Share of OTC and Prescription Drugs in Pharma Market (2011)
Figure 5-25: Vietnam - Share of Generics and Patented Drugs in Pharma Market (2011)
Figure 5-26: Thailand - Pharmaceutical Market (Billion US$), 2010-2015
Figure 5-27: Thailand - Share of Imported and Domestically Manufactured Drugs in Pharma Market (2011)
Figure 5-28: Thailand - Share of Branded and Generics Drugs in Pharma Market (2010)
Figure 5-29: Thailand - Patented Drugs Market (Billion US$), 2010-2015
Figure 5-30: Thailand - Pharmaceutical Import and Export (Billion THB), 2009-2011
Figure 5-31: Philippines - Pharmaceutical Market (Billion PHP), 2010-2015
Figure 5-32: Philippines - Share of OTC, Prescription and Nutritional Drugs in Pharma Market (2011)
Figure 5-33: Philippines - Market Structure of the Pharmaceutical Industry
Figure 5-34: Philippines - Share of Foreign and Domestic Drugs Market (2011)
Figure 5-35: Philippines - Medicinal and Pharmaceutical Products Import (Million US$), 2009-2011
Figure 5-36: Malaysia - Pharmaceutical Market (Billion MYR), 2010-2015
Figure 5-37: Malaysia - Pharmaceutical Market by Sector (%), 2009
Figure 5-38: Malaysia - Share of Generics and Branded Drugs in Pharma Market (2011)
Figure 5-39: Malaysia - Share of Imported and Domestically Manufactured Drugs in Pharma Market (2011)
Figure 5-40: Malaysia - Pharmaceutical Exports (Million MYR), 2009-2011
Figure 5-41: Australia - Pharmaceutical Market (Billion A$), FY 2010-FY 2015
Figure 5-42: Australia - Market Structure of Pharmaceutical Industry
Figure 5-43: Australia - Share of Generics and Branded Drugs in Pharma Market (FY 2011)
Figure 5-44: Australia - Share of OTC and Prescription Drugs in Pharma Market (FY 2011)
Figure 5-45: Australia - Pharmaceutical Exports and Imports (Billion A$), FY 2009-FY 2011
Figure 5-46: New Zealand - Pharmaceutical Market (Billion US$), 2010-2015
Figure 5-47: New Zealand - Share of Generics and Branded Drugs in Pharma Market (2011)
Figure 5-48: New Zealand - Share of OTC and Prescription Drugs in Pharma Market (2011)
Figure 6-1: Asia-Pacific - CRO Market (Billion US$), 2010-2015
Figure 6-2: Asia Pacific - CRO Market by Country (%), 2009
Figure 6-3: Asia-Pacific - Generic Drugs Market (Billion US$), 2008-2011
Figure 6-4: Asia - Medical Tourism Market (Billion US$), 2010-2013

List of Tables:

Table 3-1: Global - Leading Drugs by Sales (Billion US$), 2010
Table 4-1: Asia-Pacific - Pharmaceutical Market by Country (Billion US$), 2011
Table 5-1: China - Healthcare Statistics (2010-2012)
Table 5-2: China - Timeframe for New Drug Review
Table 5-3: India - Healthcare Statistics (2010-2012)
Table 5-4: India - Top Five States in Number of Pharmaceutical Manufacturing Units
Table 5-5: Japan - Healthcare Statistics (2010-2012)
Table 5-6: South Korea - Healthcare Statistics (2010-2012)
Table 5-7: Indonesia - Healthcare Statistics (2010-2012)
Table 5-8: Vietnam - Healthcare Statistics (2010-2012)
Table 5-9: Thailand - Healthcare Statistics (2010-2012)
Table 5-10: Philippines - Healthcare Statistics (2010-2012)
Table 5-11: Malaysia - Healthcare Statistics (2010-2012)
Table 5-12: Australia - Healthcare Statistics (2010-2012)
Table 5-13: New Zealand - Healthcare Statistics (2010-2012)

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Shadi

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers

Analyzing the Global Generics Industry 2014

Analyzing the Global Generics Industry 2014

  • $ 1 750
  • Industry report
  • May 2014
  • by Aruvian's R'search

In recent times there has been a growing focus on the generic drugs industry worldwide. The patent expiry of leading drugs in recent years and also the upcoming patent expiries has put a focus on the global ...

Calcitonin Gene-Related Peptide Receptor (CRLR) Antagonists -Pipeline Insights, 2014

Calcitonin Gene-Related Peptide Receptor (CRLR) Antagonists -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Calcitonin Gene-Related Peptide Receptor (CRLR) Antagonists-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action ...

Transition at Teva: Blockbuster drug Copaxone to lose patent protection in 2014

Transition at Teva: Blockbuster drug Copaxone to lose patent protection in 2014

  • $ 495
  • Industry report
  • April 2014
  • by MarketLine

Introduction In October 2013, Teva announced that it would be cutting approximately 10% of the workforce in order to cut costs. Later that month, it announced the departure of its CEO of just 18 months, ...

Global Markets For Generic Drugs

January 2014 $ 6 650

Global Hyaluronic Market 2012-2016

October 2013 $ 2 500

Global Generics, Marketline

August 2013 $ 350

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.